secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cidara Therapeutics, Inc. (—)
CIK:        0001610618
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001610618-24-000121
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cidara cuts 30% of workforce, focuses on CD388 influenza program; Phase 2b planned Q3 2024
--------------------------------------------------------------------------------

- Reduction of 20 employees (~30% of workforce); charges ~$1.2M for severance and benefits in Q4 2024.
- Workforce reduction expected to be substantially completed by November 1, 2024.
- Company will focus entirely on CD388 influenza candidate; no other clinical trials currently planned.
- Phase 2b clinical trial of CD388 for influenza prevention expected to initiate in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610618/000161061824000121/0001610618-24-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610618/000161061824000121/cdtx-20240909.htm
  HTML page:      https://secwatch.observer/filing/0001610618-24-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer